Can you provide a detailed discussion of the Ambler classification of β‑lactamases and the associated resistance patterns of Gram‑negative bacteria?

Ambler Classification of β-Lactamases and Associated Resistance Patterns

The Ambler classification divides β-lactamases into four molecular classes (A, B, C, and D) based on amino acid sequence homology, with Classes A, C, and D being serine-based enzymes and Class B being zinc-dependent metallo-β-lactamases (MBLs), each conferring distinct resistance patterns that directly dictate treatment strategies for carbapenem-resistant Gram-negative infections 1.

Molecular Classification Framework

The Ambler system represents the molecular classification standard, distinguishing enzymes by their catalytic mechanism 2, 3:

• Classes A, C, and D: Serine-based hydrolysis mechanism
• Class B: Metallo-enzymes requiring divalent zinc ions for substrate hydrolysis

This molecular framework differs from functional classification schemes but provides the foundation for understanding resistance mechanisms and predicting therapeutic responses 2.

Class-Specific Resistance Patterns in Enterobacterales

Class A Carbapenemases (KPC)

KPC enzymes represent the most prevalent carbapenemase globally (47.4% of meropenem-non-susceptible Enterobacterales), conferring resistance to virtually all β-lactams including carbapenems 1.

Key clinical characteristics:

• Hydrolyze penicillins, cephalosporins, and carbapenems
• Inhibited by avibactam, vaborbactam, and relebactam 1, 4
• Remain susceptible to novel β-lactam/β-lactamase inhibitor combinations
• First-line treatment: ceftazidime-avibactam or meropenem-vaborbactam (strong recommendation, moderate certainty) 1, 5

Class B Metallo-β-Lactamases (NDM, VIM, IMP)

MBLs are particularly concerning because they hydrolyze ALL β-lactam classes except aztreonam and are NOT inhibited by classic serine β-lactamase inhibitors (clavulanic acid, tazobactam, avibactam, vaborbactam) 1.

Critical resistance pattern:

• Account for 20.6% of carbapenem-resistant Enterobacterales 1
• Aztreonam remains active but cannot be used alone due to co-production of ESBLs 1
• Treatment requires ceftazidime-avibactam PLUS aztreonam (strong recommendation) or cefiderocol (conditional recommendation) 1
• Classic β-lactamase inhibitor combinations are ineffective 1

The inability of serine β-lactamase inhibitors to inhibit MBLs represents a fundamental mechanistic difference—these enzymes use zinc ions rather than serine for catalysis, rendering avibactam and similar inhibitors structurally incompatible 1.

Class C Cephalosporinases (AmpC)

Class C enzymes are chromosomally encoded in organisms like Enterobacter, Citrobacter, and Serratia (the "SPICE" organisms) 6, 7:

• Inducible expression leading to resistance against oxyimino-β-lactams and β-methoxy-β-lactams (cefoxitin, cefotetan)
• Carbapenems retain activity 6
• Newer inhibitors (avibactam, relebactam) demonstrate activity against AmpC producers 4, 7
• Not inhibited by clavulanic acid, sulbactam, or tazobactam 7

Class D Carbapenemases (OXA-48-like)

OXA-48-like enzymes account for 19.0% of carbapenem-resistant Enterobacterales 1:

• Variable carbapenem hydrolysis (often weak)
• Inhibited by avibactam 4, 5
• May retain susceptibility to some carbapenems depending on specific variant
• Ceftazidime-avibactam shows activity 5

Critical Clinical Implications

Rapid Identification is Essential

Because each Ambler class confers different susceptibility profiles requiring distinct treatment strategies, rapid testing to identify specific carbapenemase families (KPC, NDM, VIM, OXA-48-like) is strongly recommended (strong recommendation, moderate certainty) 1.

Time from blood culture to active antibiotic therapy directly influences mortality in critically ill patients with carbapenemase-producing infections 1. Empiric therapy based on local epidemiology must be rapidly refined once the specific enzyme class is identified.

Treatment Algorithm by Ambler Class

For Class A (KPC) producers:

• First-line: ceftazidime-avibactam OR meropenem-vaborbactam 1, 5
• Alternative: imipenem-relebactam or cefiderocol 1

For Class B (MBL) producers:

• Preferred: ceftazidime-avibactam PLUS aztreonam (19.2% vs 44% mortality compared to other regimens) 1
• Alternative: cefiderocol (75% clinical cure in MBL subgroup) 1
• Avoid: ceftazidime-avibactam or meropenem-vaborbactam monotherapy—these are INACTIVE against MBLs 1

For Class D (OXA-48-like) producers:

• Ceftazidime-avibactam demonstrates activity 5
• Evidence remains limited (very low certainty) 1

For Class C (AmpC) producers:

• Carbapenems remain effective 6
• Newer combinations (ceftazidime-avibactam, ceftolozane-tazobactam) show activity 4, 5

Common Pitfalls and Caveats

Resistance Emergence During Therapy

Ceftazidime-avibactam resistance can emerge in KPC-producing isolates during treatment (3.7-8.1% of treated patients) through amino acid mutations in the KPC omega loop 5. This occurs regardless of prior exposure and represents a critical limitation requiring surveillance.

Co-production of Multiple Enzymes

MBL producers frequently co-produce ESBLs and other cephalosporinases, which is why aztreonam—though stable to MBLs—cannot be used as monotherapy 1. The combination with ceftazidime-avibactam (which inhibits the co-produced ESBLs) restores aztreonam activity.

Geographic Variation

Carbapenemase epidemiology varies dramatically by region. KPC predominates in the United States and Mediterranean Europe, while NDM is endemic in the Indian subcontinent with increasing European spread 1. Local epidemiology should guide empiric therapy pending rapid diagnostic results.

Mechanism-Independent Resistance

Not all carbapenem resistance is carbapenemase-mediated. Porin loss combined with ESBL or AmpC production can confer carbapenem resistance without carbapenemase production 1. These isolates may respond differently to novel agents and require individualized susceptibility testing.

Pseudomonas aeruginosa and Acinetobacter Considerations

In P. aeruginosa, Class B metallo-β-lactamases (IMP, VIM) confer resistance to carbapenems and antipseudomonal penicillins/cephalosporins, with some MDR isolates susceptible only to polymyxin B 6.

In Acinetobacter species, carbapenem resistance increasingly results from IMP-type MBLs or OXA-type carbapenemases (Class D), with >85% historically susceptible to carbapenems but resistance rising 6.

The Ambler classification provides the molecular framework essential for predicting antibiotic susceptibility and guiding targeted therapy in an era of escalating carbapenem resistance.